西洛他唑治疗预防2型糖尿病合并冠状动脉粥样硬化患者不良心血管事件:ESCAPE研究的长期随访
Abstract Background Previously, in the ESCAPE study, a randomized controlled trial, we found that 12 months of cilostazol administration significantly decreased coronary artery stenosis and the noncalcified plaque component compared with aspirin. The goal of the current study was to evaluate the eff...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-08-01
|
| Series: | Journal of Diabetes |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1753-0407.13300 |
| _version_ | 1811301369377718272 |
|---|---|
| author | Minji Sohn Eun Ju Chun Soo Lim |
| author_facet | Minji Sohn Eun Ju Chun Soo Lim |
| author_sort | Minji Sohn |
| collection | DOAJ |
| description | Abstract Background Previously, in the ESCAPE study, a randomized controlled trial, we found that 12 months of cilostazol administration significantly decreased coronary artery stenosis and the noncalcified plaque component compared with aspirin. The goal of the current study was to evaluate the effect of cilostazol treatment on cardiovascular events up to 7 years after the end of the original study. Methods After the end of the ESCAPE study with patients with type 2 diabetes mellitus (T2DM) and mild to moderate coronary artery stenosis, we decided to extend the ESCAPE study to investigate the long‐term effect of cilostazol and aspirin, named the ESCAPE‐extension study. The study participants had been investigated for cardiovascular events for up to 7 years, bringing the total follow‐up time to a median of 5.2 years (interquartile range 3.6‐6.7 years). Adverse events were also investigated. Results Among 100 participants from the original study, 88 were included in this extension study. Cilostazol treatment reduced the incidence of cardiovascular events in the patients with T2DM when compared with aspirin for a 5.2‐year median follow‐up (hazard ratio 0.24; 95% CI, 0.07‐0.83). The cardiovascular benefit of cilostazol therapy was maintained along with age, sex, systolic blood pressure, low‐density lipoprotein cholesterol, and coronary artery calcium score. No serious adverse events in the cilostazol group were noted in the follow‐up period. Conclusions In this ESCAPE‐extension study, cilostazol treatment proved its efficacy in reducing cardiovascular events compared with aspirin in diabetic patients with subclinical coronary artery disease, suggesting the beneficial role of cilostazol in the primary prevention of cardiovascular disease. |
| first_indexed | 2024-04-13T07:07:37Z |
| format | Article |
| id | doaj.art-5dfb75f810c24d6289340b94f593cc6b |
| institution | Directory Open Access Journal |
| issn | 1753-0393 1753-0407 |
| language | English |
| last_indexed | 2024-04-13T07:07:37Z |
| publishDate | 2022-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes |
| spelling | doaj.art-5dfb75f810c24d6289340b94f593cc6b2022-12-22T02:56:57ZengWileyJournal of Diabetes1753-03931753-04072022-08-0114852453110.1111/1753-0407.13300西洛他唑治疗预防2型糖尿病合并冠状动脉粥样硬化患者不良心血管事件:ESCAPE研究的长期随访Minji Sohn0Eun Ju Chun1Soo Lim2Department of Internal Medicine Seoul National University Bundang Hospital, Seoul National University College of Medicine Seongnam Republic of KoreaDepartment of Radiology Seoul National University Bundang Hospital, Seoul National University College of Medicine Seongnam Republic of KoreaDepartment of Internal Medicine Seoul National University Bundang Hospital, Seoul National University College of Medicine Seongnam Republic of KoreaAbstract Background Previously, in the ESCAPE study, a randomized controlled trial, we found that 12 months of cilostazol administration significantly decreased coronary artery stenosis and the noncalcified plaque component compared with aspirin. The goal of the current study was to evaluate the effect of cilostazol treatment on cardiovascular events up to 7 years after the end of the original study. Methods After the end of the ESCAPE study with patients with type 2 diabetes mellitus (T2DM) and mild to moderate coronary artery stenosis, we decided to extend the ESCAPE study to investigate the long‐term effect of cilostazol and aspirin, named the ESCAPE‐extension study. The study participants had been investigated for cardiovascular events for up to 7 years, bringing the total follow‐up time to a median of 5.2 years (interquartile range 3.6‐6.7 years). Adverse events were also investigated. Results Among 100 participants from the original study, 88 were included in this extension study. Cilostazol treatment reduced the incidence of cardiovascular events in the patients with T2DM when compared with aspirin for a 5.2‐year median follow‐up (hazard ratio 0.24; 95% CI, 0.07‐0.83). The cardiovascular benefit of cilostazol therapy was maintained along with age, sex, systolic blood pressure, low‐density lipoprotein cholesterol, and coronary artery calcium score. No serious adverse events in the cilostazol group were noted in the follow‐up period. Conclusions In this ESCAPE‐extension study, cilostazol treatment proved its efficacy in reducing cardiovascular events compared with aspirin in diabetic patients with subclinical coronary artery disease, suggesting the beneficial role of cilostazol in the primary prevention of cardiovascular disease.https://doi.org/10.1111/1753-0407.13300关键词:2型糖尿病心血管疾病动脉粥样硬化血小板聚集抑制剂 |
| spellingShingle | Minji Sohn Eun Ju Chun Soo Lim 西洛他唑治疗预防2型糖尿病合并冠状动脉粥样硬化患者不良心血管事件:ESCAPE研究的长期随访 Journal of Diabetes 关键词:2型糖尿病 心血管疾病 动脉粥样硬化 血小板聚集抑制剂 |
| title | 西洛他唑治疗预防2型糖尿病合并冠状动脉粥样硬化患者不良心血管事件:ESCAPE研究的长期随访 |
| title_full | 西洛他唑治疗预防2型糖尿病合并冠状动脉粥样硬化患者不良心血管事件:ESCAPE研究的长期随访 |
| title_fullStr | 西洛他唑治疗预防2型糖尿病合并冠状动脉粥样硬化患者不良心血管事件:ESCAPE研究的长期随访 |
| title_full_unstemmed | 西洛他唑治疗预防2型糖尿病合并冠状动脉粥样硬化患者不良心血管事件:ESCAPE研究的长期随访 |
| title_short | 西洛他唑治疗预防2型糖尿病合并冠状动脉粥样硬化患者不良心血管事件:ESCAPE研究的长期随访 |
| title_sort | 西洛他唑治疗预防2型糖尿病合并冠状动脉粥样硬化患者不良心血管事件 escape研究的长期随访 |
| topic | 关键词:2型糖尿病 心血管疾病 动脉粥样硬化 血小板聚集抑制剂 |
| url | https://doi.org/10.1111/1753-0407.13300 |
| work_keys_str_mv | AT minjisohn xīluòtāzuòzhìliáoyùfáng2xíngtángniàobìnghébìngguānzhuàngdòngmàizhōuyàngyìnghuàhuànzhěbùliángxīnxuèguǎnshìjiànescapeyánjiūdezhǎngqīsuífǎng AT eunjuchun xīluòtāzuòzhìliáoyùfáng2xíngtángniàobìnghébìngguānzhuàngdòngmàizhōuyàngyìnghuàhuànzhěbùliángxīnxuèguǎnshìjiànescapeyánjiūdezhǎngqīsuífǎng AT soolim xīluòtāzuòzhìliáoyùfáng2xíngtángniàobìnghébìngguānzhuàngdòngmàizhōuyàngyìnghuàhuànzhěbùliángxīnxuèguǎnshìjiànescapeyánjiūdezhǎngqīsuífǎng |